|
🦁
|
Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease
A. Wasilewski,
M. Zielińska,
M. Storr,
J. Fichna
|
7 |
2015 |
7
🦁
|
|
🐬
|
Role of Transient Receptor Potential Channels in Intestinal Inflammation and Visceral Pain: Novel Targets in Inflammatory Bowel Diseases
M. Zielińska,
Agata Jarmuż,
A. Wasilewski,
M. Sałaga,
J. Fichna
|
5 |
2015 |
5
🐬
|
|
🦁
|
Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome
7 auth.
A. Wasilewski,
U. Lewandowska,
P. Mosińska,
C. Watała,
M. Storr,
J. Fichna,
...
T. Venkatesan
|
5 |
2017 |
5
🦁
|
|
🦁
|
Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study.
A. Wasilewski,
U. Krajewska,
K. Owczarek,
U. Lewandowska,
J. Fichna
|
5 |
2017 |
5
🦁
|
|
🐜
|
Polymorphisms of Homologous Recombination RAD51, RAD51B, XRCC2, and XRCC3 Genes and the Risk of Prostate Cancer
8 auth.
Maria Nowacka-Zawisza,
Ewelina Wiśnik,
A. Wasilewski,
M. Skowrońska,
E. Forma,
M. Bryś,
...
W. Różański,
W. Krajewska
|
4 |
2015 |
4
🐜
|
|
🐬
|
Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome
M. Zielińska,
A. Wasilewski,
J. Fichna
|
4 |
2015 |
4
🐬
|
|
🐜
|
Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract
7 auth.
A. Szymaszkiewicz,
J. Włodarczyk,
A. Wasilewski,
V. Di Marzo,
M. Storr,
J. Fichna,
...
M. Zielińska
|
3 |
2020 |
3
🐜
|
|
🦁
|
Role of G Protein-coupled Orphan Receptors in Intestinal Inflammation: Novel Targets in Inflammatory Bowel Diseases
A. Wasilewski,
M. Storr,
M. Zielińska,
J. Fichna
|
3 |
2015 |
3
🦁
|
